Previous Close | 0.0050 |
Open | 0.0000 |
Bid | 0.0000 x 0 |
Ask | 0.0050 x 0 |
Day's Range | 0.0050 - 0.0050 |
52 Week Range | 0.0050 - 0.0050 |
Volume | |
Avg. Volume | 0 |
Market Cap | 3.67M |
Beta (5Y Monthly) | 0.75 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0600 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 0.05 |
GABY Inc. (GABY or the Company) (CSE:GABY) (OTC PINK:GABLF) has determined that consistent with and as reported in its consolidated audited financial statements for the year ended December 31, 2022, the write down of its Type 10 retail license issued by the California Department of Cannabis Control to its wholly owned subsidiary, Miramar Professional Services (MPS) renders the value of such asset below the remaining debt of $22.5 Million incurred
GABY Inc. ("GABY" or the "Company") (CSE:GABY)(OTCQB:GABLF), a California consolidator of cannabis dispensaries and the parent company of San Diego's Mankind Dispensary ("Mankind"), announces that it will not be proceeding with the proposed transaction with HempFusion Wellness Inc. ("HempFusion") as announced in the Company's news release on April 28, 2023.
GABY Inc. ("GABY" or the "Company") (CSE:GABY)(OTCQB:GABLF), a California consolidator of cannabis dispensaries and the parent company of San Diego's Mankind Dispensary ("Mankind"), reported its financial and operating results for the quarter and fiscal year end December 31, 2022 ("Q4 2022"). All financial information is provided in United States dollars unless otherwise indicated.